Cerimon Pharmaceuticals

About:

Cerimon Pharmaceuticals develops and commercializes therapeutics for autoimmune diseases, inflammation, and pains.

Top Investors: OrbiMed, MPM Capital, Phase4 Ventures

Description:

Cerimon Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for autoimmune diseases, inflammation, and pains in the United States and Europe. It develops Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, including pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. Cerimon Pharmaceuticals, Inc. was founded in 2004 and is headquartered in South San Francisco, California.

Total Funding Amount:

$72.7M

Headquarters Location:

South San Francisco, California, United States

Founded Date:

2004-01-01

Founders:

Ansbert Gadicke, Luke Evnin, Paul Sekhri

Number of Employees:

11-50

Last Funding Date:

2010-11-15

IPO Status:

Private

Industries: